



December 10, 2021

BSE Limited
Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards launch of Diagnostics business in India.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,
For LUPIN LIMITED



R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Announces the Launch of its Diagnostics Business
Reaffirms its Commitment to Building an Integrated Healthcare Proposition in India

Mumbai, India, December 10, 2021: Global pharma major Lupin Limited (Lupin) today announced the launch of Lupin Diagnostics in India. As part of its strategy to provide integrated healthcare in India, Lupin Diagnostics, a wholly owned subsidiary of Lupin has formally commenced operations.

With healthcare playing an increasingly important role, Lupin Diagnostics' goal is to provide quality diagnostics services to doctors, patients and consumers. The company has established a state-of-the-art 45,000 sq. ft National Reference Laboratory in Navi Mumbai. With world-class equipments, experienced doctors assisted by trained technologists, and stringent quality control protocols, Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.

Commenting on this development, Mr. Nilesh Gupta, Managing Director, Lupin said, "The health and well-being of our customers is our top priority at Lupin. Combining decades of experience and knowledge in the field of therapeutics, we aim to provide our doctors, patients and consumers with the same experience offering quality diagnostic services that are built on trust. I am delighted to announce the launch of Lupin Diagnostics enabling customers across India to obtain more accurate results with personalized insights, built on a backbone of quality standards and controls that are unrivalled. Our experienced team of Pathologists, Microbiologists, and Geneticists, along with a trained technical support team will ensure that each customer receives high quality diagnostic care."

"The pandemic has elevated healthcare to the top of the global agenda. The role of diagnostics is crucial to improving the health and well-being of society," said **Rajeev Sibal, President, India Region Formulations, Lupin**. "We are pleased to announce the launch of Lupin Diagnostics, which will provide consumers with the best-in-class diagnostics services with the highest quality standards in the industry. With a world-class infrastructure and equipment, seasoned doctors, supported by well-qualified technologists, we will provide a comprehensive array of diagnostic tests."

"Doctors increasingly rely on high quality diagnostic tests to formulate a treatment and disease management plan that is evidence-based. Diagnostics results are an important part of this decision-making while managing the journey of a patient," said **Ravindra Kumar, Vice President & Head, Lupin Diagnostics**. "By building on Lupin's market leadership position, we are well-positioned to lead and shape Lupin's diagnostics business in India."



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

The core facilities of the laboratory include all major diagnostics services, preventive health check-ups, and a comprehensive range of tests. All the processing will be operated by Lupin Healthcare as a hub and will be connected to a nation-wide network of regional, satellite and collection centers. In addition, Lupin is identifying franchisee partners who are willing to serve the needs of patients with a singular motto of 'Quality & Care'.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

About Lupin Diagnostics

Lupin Diagnostics is a part of Lupin Healthcare Limited, which is a 100% subsidiary of Lupin Limited. The company is headquartered in Mumbai with National Reference Laboratory in Navi Mumbai. All the processing laboratories are operated by Lupin Diagnostics as a hub and spoke model.

It includes Collection Centres, Pick-up Points, Hospital Laboratory Management, Retail Laboratory Management, and Home Collection pan-India. The operations for Lupin Diagnostics have commenced from October 2021.

For more information browse through: <https://bit.ly/Lupin-Diagnostics>

For further information or queries please contact:

Shweta Munjal

Vice President & Global Head - Corporate Communications

Email: shwetamunjal@lupin.com

Naini Thakkar

Email: nainithakkar@lupin.com

9820250939